Researchers reported that daraxonrasib, a novel pill targeting a mutated protein responsible for tumor growth in over 90% of pancreatic cancer cases, nearly doubled the median survival time for patients with metastatic pancreatic cancer. In a study involving 500 patients, those taking the drug lived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy.
This marks the first time a drug has demonstrated a substantial advantage over chemotherapy in this context. The study, led by Dr. Zev Wainberg from UCLA, was published in the New England Journal of Medicine and presented at the American Society for Clinical Oncology meeting. The drug's ability to provide a durable benefit, with fewer severe side effects, has led experts like Dr.
Rachna Shroff to express optimism about its potential impact on treatment protocols. The FDA plans to expedite its review and has allowed expanded access for eligible patients. The drug's mechanism involves binding to KRAS mutations, which have historically been difficult to target, suggesting a shift in the treatment landscape for pancreatic cancer.
As the drug continues to be evaluated, there is hope that it could become a new standard of care and potentially allow for earlier intervention in the disease process